brain cancer

View All

Latest Pharma News for VistaGen and Merck
VistaGen’s PH94B for Anxiety Disorder; Keytruda for Head and Neck Cancer Treatment; Bavarian Nordic’s Smallpox Vaccine Imvanex; CAMP4 Raises USD 100 Million; Incyte’s WU-CART-007; Incyte’s Opzelura for Vitiligo; AstraZeneca and Merck’s Lynparza; Sumitomo Pharma’s DSP-0390 for Brain Cancer

FDA Approves Incyte’s Opzelura as First Vitiligo Therapy The US Food and Drug Administration has approved Incyte’s Opzelura cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age and older. With this approval, Opzelura is the first and only FDA-approved...

Find More

Biogen terminates ALS Pact with Karyopharm; AbbVie’s Immunological Drug Skyrizi; NICE Backs Astellas’ Oral Therapy Evrenzo; Roche’s Crenezumab Fails in Clinical Trial; FDA Grants Fast Track Designation to Dianhydrogalactitol; Sierra Oncology Submits NDA for Momelotinib

Biogen terminates USD 217 Million ALS Pact with Karyopharm Biogen has backed out of the four-year-old partnership with Karyopharm on a drug candidate for the neurological disease amyotrophic lateral sclerosis, which could have cost the US biotech up to USD 217 million. The 2018 agreement that granted Biogen righ...

Find More

medtech-news-and-updates-for-ossur-depuy-myomo-accuray-theradaptive-senseonics
Össur Launches POWER KNEE; DePuy Synthes Acquires CrossRoads Extremity Systems; Myomo’s MyoPro; Accuray’s TomoTherapy System; Theradaptive’s Spinal Fusion Implant; Senseonics’s Eversense E3 CGM System

Össur Launches World’s Actively Powered Lower Limb Bionic Prosthesis- New Power Knee for Amputees On February 09, 2022, Össur announced the launch of the new POWER KNEE, the first actively powered microprocessor-based prosthetic knee in the world. This device is aimed at treating patients with above-knee amputat...

Find More

pharma-news-for-noxxon-nuvalent-stryker-exact-sciences
Noxxon’s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent’s clinical trails for NVL-520; Stryker acquires Vocera Communications

Noxxon continues enrolment in a glioblastoma therapy trial Noxxon Pharma continues subject enrolment in the GLORIA clinical trial of NOX-A12 in brain cancer (glioblastoma) patients. The move comes after the Data Safety Monitoring Board (DSMB) evaluated safety results from the preliminary four-week treatment with...

Find More

GBM-Market-Glioblastoma-Multiforme-Therapeutic-Advancements
Glioblastoma Multiforme: Advancements in the Treatment Paradigm of the Malignant Condition

Over the past decades, there has been an eruption in understanding treatment strategies of gliomas with the development of clinical immunotherapy, providing exceptional success in employing checkpoint inhibitors and cancer vaccines as treatment options that have given significant momentum to the growth of the GBM m...

Find More

LITT
The novel therapy for brain cancer treatments

Laser Interstitial Thermal Therapy (LITT) is one of a hopeful treatment for brain cancer. Now, researchers are also using lasers to activate cancer-destroying drugs and other groups are testing the use of electrical fields to intersect the cancer cells division. The researchers are yet to determine the effectiveness...

Find More

Identity Crises Faced by a Venerable Brain-Cancer Cell Line

There has been a shocking revelation in a report published in Science Translational Medicine by Bengt Westermark, a tumour biologist at Uppsala, who reports that a cell line widely used to study brain cancer does not match the cells used to create the line nearly 50 years ago, or the tumour supposed to be its source...

Find More